Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety
Authors:
Top Cited Papers
Open Access
- 7 January 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pain Research
- Vol. 5, 1513597
Abstract
Introduction: Neuropathic pain is a prevalent and burdensome condition, and both pregabalin and gabapentin are widely used for its treatment. However, there is a lack of clarity regarding their comparative efficacy and safety. This meta-analysis aims to evaluate and compare the effectiveness and safety of pregabalin vs. gabapentin in managing neuropathic pain.Methods: This study followed PRISMA guidelines and employed the PICOS search strategy. Comparative studies (clinical trials and cohort studies) were included, with patients with neuropathic pain treated either with pregabalin or gabapentin. Primary outcomes assessed were efficacy and safety. Data were extracted from PubMed, Embase, Scopus, and the Cochrane Collaboration Library databases. The risk of bias was evaluated using the Cochrane Review Manager tool. Statistical analysis was performed using Review Manager 5.4.1 software, calculating effect sizes and conducting sensitivity analysis based on medication dosage.Results: A total of 14 studies with 3,346 patients were analyzed. Pregabalin showed superior results compared to gabapentin in the Visual Analog Scale (VAS) at various time intervals up to 12–14 weeks (SMD −0.47, 95% CI −0.74 to −0.19). The pregabalin group also had significant improvements in SF-12/SF-36/EQ-5D scores (SMD 0.39, 95% CI 0.11–0.68) and experienced more days with no/mild pain (MD 9.00, 95% CI 8.93–9.07) and fewer days with severe pain (MD −3.00, 95% CI −4.96 to −1.04). Pregabalin resulted in lower opioid consumption (OR 0.50, 95% CI 0.33–0.76). Gabapentin had a higher incidence of nausea and vomiting. Sensitivity analysis supported the efficacy of pregabalin.Conclusion: In conclusion, pregabalin demonstrated superior and faster efficacy in alleviating neuropathic pain than gabapentin did. Additionally, it improved patient-reported outcomes, resulted in lower opioid consumption, and led to fewer adverse events.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=565208, PROSPERO (CRD42024565208).Keywords
This publication has 67 references indexed in Scilit:
- Opioid-Induced Tolerance and HyperalgesiaCNS Drugs, 2019
- Cochrane Handbook for Systematic Reviews of Interventions2019
- Gabapentenoids in pain management in urological chronic pelvic pain syndrome: Gabapentin or pregabalin?Neurourology and Urodynamics, 2017
- Gabapentinoids Are Effective in Decreasing Neuropathic Pain and Other Secondary Outcomes After Spinal Cord Injury: A Meta-AnalysisArchives of Physical Medicine and Rehabilitation, 2014
- Gabapentin Enhances the Morphine Anti-Nociceptive Effect in Neuropathic Pain via the Interleukin-10-Heme Oxygenase-1 Signalling Pathway in RatsJournal of Molecular Neuroscience, 2014
- Cross-Over, Open-Label Trial of the Effects of Gabapentin versus Pregabalin on Painful Peripheral Neuropathy and Health-Related Quality of Life in Haemodialysis PatientsClinical Drug Investigation, 2013
- Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control studyClinical Therapeutics, 2010
- Reduction of secondarily generalized tonic–clonic (SGTC) seizures with pregabalinEpilepsy Research, 2008
- A Retrospective Evaluation of the Use of Gabapentin and Pregabalin in Patients with Postherpetic Neuralgia in Usual-Care SettingsClinical Therapeutics, 2007
- Pharmacology and mechanism of action of pregabalin: The calcium channel α2–δ (alpha2–delta) subunit as a target for antiepileptic drug discoveryEpilepsy Research, 2007